Welcome to our dedicated page for Replimune Group SEC filings (Ticker: REPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Replimune Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Replimune Group's regulatory disclosures and financial reporting.
Replimune Group director Philip Astley-Sparke reported compensation-related equity awards. He received a stock option for 75,000 shares of common stock at an exercise price of 7.6100 per share, expiring on April 1, 2036. Twenty-five percent of this option vests on April 1, 2027, with the rest vesting in 36 approximately equal monthly installments.
He also received 50,000 shares of common stock issuable upon settlement of restricted stock units, with 25% vesting on May 15, 2027 and the remainder in three approximately equal annual installments through May 15, 2030, subject to continuous service. Following the grant, he directly holds 1,430,071 common shares. These are grants/awards, not open-market purchases or sales.
Replimune Group, Inc. director Christy J. Oliger received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036.
According to the filing footnote, all shares underlying this option vest on April 1, 2027. Following this grant, Oliger holds stock options for 44,500 shares directly, reflecting a compensation-related award rather than an open-market trade.
Replimune Group, Inc. reported that Chief Medical Officer Konstantinos Xynos received new equity awards as part of his compensation. He was granted an employee stock option for 75,000 shares of common stock at an exercise price of $7.61 per share, expiring on April 1, 2036. Twenty‑five percent of these option shares will vest on April 1, 2027, with the remainder vesting in 36 roughly equal monthly installments.
He also acquired 50,000 shares of common stock through restricted stock units (RSUs). Each RSU represents one share of common stock, with 25% vesting on May 15, 2027 and the rest vesting in three approximately equal annual installments until May 15, 2030, subject to continued service. Following these grants, he directly owns 249,685 common shares.
Replimune Group, Inc. director Madhavan Balachandran received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. According to the footnote, all underlying shares vest on April 1, 2027.
Replimune Group, Inc. reported that Chief Accounting Officer Andrew Schwendenman received new equity awards. He was granted an employee stock option for 55,000 shares of common stock at an exercise price of $7.61 per share, vesting 25% on April 1, 2027 and then in 36 monthly installments until expiration on April 1, 2036. He was also awarded 36,667 shares of common stock issuable upon settlement of restricted stock units, vesting 25% on May 15, 2027 and then in three annual installments through May 15, 2030, contingent on continued service. Following these grants, he directly holds 114,951 shares of common stock, plus the newly granted options.
Replimune Group, Inc. disclosed that Chief Executive Officer Sushil Patel received new equity awards as part of his compensation. He was granted an employee stock option for 376,860 shares of common stock at an exercise price of $7.61 per share, expiring on April 1, 2036. According to the vesting schedule, 25% of the option vests on April 1, 2027, with the remainder vesting in 36 approximately equal monthly installments. Patel also received 251,240 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest 25% on May 15, 2027, with the balance vesting in three approximately equal annual installments through May 15, 2030, contingent on continued service. Following these awards, he directly owns 784,816 shares of common stock. These are compensation-related grants rather than open-market purchases.
Replimune Group director Kapil Dhingra received a grant of stock options covering 44,500 shares of Common Stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. All underlying shares vest together on April 1, 2027, and no open-market buy or sell occurred.
Replimune Group, Inc. director Paolo Pucci received a grant of stock options covering 44,500 shares of Common Stock. The options have a per-share exercise price of $7.61 and expire on April 1, 2036. All underlying shares vest in a single tranche on April 1, 2027. This is a compensation-related award rather than an open-market purchase or sale, and after this grant Pucci holds 44,500 stock options directly.
Replimune Group, Inc. director Joseph P. Slattery received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. According to the disclosure, all 44,500 underlying shares vest in full on April 1, 2027. Following this grant, Slattery holds 44,500 stock options directly.
Replimune Group, Inc. director Veleka Peeples-Dyer received a grant of stock options covering 44,500 shares of common stock. The options have an exercise price of $7.61 per share and expire on April 1, 2036. All underlying shares vest on April 1, 2027, making this a compensation-related, non-market transaction.